Guru Sonpavde, MD
Enriched profileMedical Director of Genitourinary (GU) Oncology and Phase I Clinical Trials; Christopher K. Glanz Chair for Bladder Cancer Research; Assistant Director of the Clinical Research Unit, AdventHealth Cancer Institute · AdventHealth Cancer Institute
Guru Sonpavde is Medical Director of Genitourinary (GU) Oncology and Phase I Clinical Trials; Christopher K. Glanz Chair for Bladder Cancer Research; Assistant Director of the Clinical Research Unit, AdventHealth Cancer Institute at AdventHealth Cancer Institute. OpenAlex indexes 1,124 publications with 27,746 citations (h-index 77); ClinicalTrials.gov lists 17 registered studies with this person as an investigator.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Guru P. Sonpavde is Medical Director of Genitourinary (GU) Oncology and Phase I Clinical Trials at AdventHealth Cancer Institute, Orlando, Florida. The public record shows 1,124 publications with 27,746 citations (h-index 77), centered on Bladder and Urothelial Cancer Treatments, Cancer Immunotherapy and Biomarkers, Urinary and Genital Oncology Studies. It also documents an investigator role on 14 registered clinical trials.
- Most recent indexed publication: 2026 · JCO precision oncology
- Top research focus: Bladder and Urothelial Cancer Treatments
- 14 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 32 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 390.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 17 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Sponsor: Eli Lilly and Company
- Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy
Sponsor: Guru Sonpavde
- A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Sponsor: NiKang Therapeutics, Inc.
Industry payments
35 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202518 payments$37,894openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202510 payments$23,160openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year20258 payments$10,488openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
64.7%Cytochrome P450 17A1 Inhibitor43.7%Abiraterone Acetate100%Part D≥44 patientsAndrogen Receptor Inhibitor10.2%Bicalutamide68%Xtandi32%Part D<11 patientsMetabolism & gastrointestinal
28.3%Corticosteroid19.5%Prednisone100%Part D≥52 patientsSerotonin-3 Receptor Antagonist6.1%Ondansetron Hcl100%Part D≥25 patientsNervous system
5.3%Phenothiazine2.8%Prochlorperazine Maleate100%Part D≥14 patientsOpioid Agonist2.5%Oxycodone Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial.
Nature medicine
Clinical Trial2026 - Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.
CA: a cancer journal for clinicians
Article2026 - Toward a better pan-tumor predictive signature for unleashing precision immuno-oncology.
Journal for immunotherapy of cancer
Review2025 - Clinical perspective on management of key adverse events with sacituzumab govitecan.
The oncologist
Review2025
Most-cited works
by citation count (OpenAlex)- 01
- 02Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma1,162 citations2021
- 03
- 04Prostate Cancer, Version 1.2016655 citations2016
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/guru-sonpavde-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/guru-sonpavde-md-ba932778
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Guru-Sonpavde-2
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Instagram
instagram.com/p/DScY6-WCqJf
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Other
bcan.org/staff/guru-p-sonpavde-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcan.org ↗ - Apple Podcasts
podcasts.apple.com/us/podcast/bladder-cancer-matters/id1550333526
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →podcasts.apple.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Christian Medical College, Vellore, India
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hoosiercancer.org ↗ - Internal Medicine Residency
Nassau University Medical Center, East Meadow, New York
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hoosiercancer.org ↗ - Hematology-Oncology Fellowship
Indiana University Medical Center, Indianapolis, Indiana
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hoosiercancer.org ↗ - Board Certified
Medical Oncology, American Board of Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
Editorial & leadership roles
journal and society appointments- Medical Director of Genitourinary Oncology
AdventHealth Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcan.org ↗ - Member
Scientific Advisory Board, Bladder Cancer Advocacy Network (BCAN)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcan.org ↗ - Member
Southwest Oncology Group (SWOG)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcan.org ↗
Secondary affiliations
appointments beyond the home institution- Formerly: Bladder Cancer Director
Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School
2022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hoosiercancer.org ↗ - Formerly: GU Oncology Director and Associate Professor of Medicine
University of Alabama at Birmingham
2017provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bcan.org ↗ - Professor of Medicine
University of Central Florida
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →grandroundsinurology.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.